Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis

Trachana, Maria; Pratsidou-Gertsi, Polyxeni; Pardalos, G; Kozeis, Nikolaos; Badouraki, Maria; Kanakoudi-Tsakalidou, F

doi:10.3109/03009742.2010.517546

Cited by 42 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, several different agents were shown to be safe in this patient population. Other studies have shown similarly reassuring results in regards to the safety of using high dose biologics [5,6] and we believe that additional study is needed to affirm this treatment approach in recalcitrant disease states. Despite the limitations acknowledged, we did observe improvement in this group of patients with serious disease or previously unresponsive to standard dose therapy.…”

Section: Discussionsupporting

confidence: 60%

“…Treatment of these diseases has only relatively recently included the use of biologic response modifiers, in particular Tumor Necrosis Factor (TNF) inhibitors [2]. Previous studies have shown the safety and efficacy of biologics in the treatment of pediatric inflammatory diseases [3][4][5][6]. Recent studies have also shown that higher dose treatment can lead to improved responses in children with some refractory diseases [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

“…In regard to the safety of biologics, there have been increasing data on long-term outcomes, with reassuring findings reported in several studies [5,[10][11][12][13]. However, the safety and efficacy of higher dose biologics for pediatric patients with a diversity of diseases have not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and Efficacy of High-dose Tumor Necrosis Factor (TNF) Inhibitors in the Management of Pediatric Inflammatory Diseases

Sarkissian¹,

Birmingham²

2015

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

Objectives: To review a cohort of patients receiving higher than standard or FDA approved dosing of TNF inhibitors to assess the safety and efficacy of these agents in the management of inflammatory joint and eye disease in a clinical pediatric rheumatology setting. Methods:A retrospective review was performed of patients 1-17 years of age with inflammatory diseases requiring TNF inhibitor therapy treated with at least six weeks of treatment of a higher than the standard FDA approved dose of TNF inhibitors, from 12/1/11-4/8/14. Entanercept (Enbrel) was given at doses greater than 0.8 mg/kg, Infliximab (Remicade) was infused in doses greater than 5 mg/kg or more frequently than every eight weeks, and Adalimumab (Humira) was given at either 20 mg/kg weekly for patients weighing less than 30 kg or 40 mg/kg weekly for patients weighing greater than 30 kg. Serious adverse events (SAE), infections, and infusion reactions were all documented. We also noted clinical improvement based on parent/patient's report of decreased symptoms and provider assessment, including exam findings and laboratory parameters. Results:Thirty-five patients were included (average 11.3 years). Of these, 24 (68%) were noted to have improvement of either symptoms or exam. There was one SAE noted in the group and one infusion reaction, and 10 patients with illnesses that may have been exacerbated by immune suppression. Conclusion:Higher than standard-dose or FDA approved dosing of TNF inhibitors appear safe and efficacious in the management of pediatric inflammatory diseases, however, caution must be taken with interpretation of the results due to the retrospective chart review study design. Larger, prospective, controlled studies will be necessary to more fully evaluate safety and efficacy of this treatment approach.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of High-dose Tumor Necrosis Factor (TNF) Inhibitors in the Management of Pediatric Inflammatory Diseases

Sarkissian¹,

Birmingham²

2015

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

show abstract

“…Наиболее часто регистрировались реакции в месте введения и инфузионные реакции, а также инфекции дыхательных путей, кожи и мочевыводящих путей [57,58].…”

Section: контроль леченияunclassified

Treatment Approach for Juvenile Idiopathic Arthritis-Related Uveitis: 2012 Update

Zulian¹,

Бироло²,

Zannin³

2012

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

show abstract

“…Так, в американском регистре CARRA больных с ЮИА 65% пациентов с сЮИА получали анти-ФНО ␣-терапию [48]; согласно греческому регистру, ада-лимумабом лечились 15% детей с сЮИА [49].…”

unclassified

Treatment with Genetically Engineered Biological Agents: Efficacy and Safety of Changeover

Baranov¹,

Alexeeva²,

Валиева³

et al. 2014

View full text Add to dashboard Cite

ВВЕДЕНИЕЮвенильный идиопатический артрит (ЮИА) -поли-генное, мульфакториальное заболевание с очень слож-ным иммуноагрессивным патогенезом [1].До 1990 г. лечение ЮИА было основано на принци-пе пирамиды: его начинали с нестероидных противовос-палительных препаратов (НПВП) и глюкокортикоидов (ГК), к которым постепенно добавляли другие иммуно-депрессанты [2].За последние 15 лет подходы к терапии ЮИА изме-нились. Благодаря разработке нового класса препара-тов, обладающих способностью селективно блокиро-Терапия генно-инженерными биологическими препаратами: эффективность и безопасность переключения ( Вопросы современной педиатрии. 2014; 13 (1): 33-50)

show abstract

Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis

Abstract: AD was safe and efficacious during the study period in the majority of patients. However, vigilance is required for the early detection of severe and potentially fatal infections. AD may control recurrent uveitis and radiological progression.

Cited by 42 publications

References 30 publications

Safety and Efficacy of High-dose Tumor Necrosis Factor (TNF) Inhibitors in the Management of Pediatric Inflammatory Diseases

Safety and Efficacy of High-dose Tumor Necrosis Factor (TNF) Inhibitors in the Management of Pediatric Inflammatory Diseases

Treatment Approach for Juvenile Idiopathic Arthritis-Related Uveitis: 2012 Update

Treatment with Genetically Engineered Biological Agents: Efficacy and Safety of Changeover

Contact Info

Product

Resources

About